Protocol Summaries: GSK2132231A
| GSK Study ID |
Phase | Title | Status |
|---|---|---|---|
| 111473 | phase 2 | Clinical activity, safety and immunogenic properties of cancer immunotherapeutic GSK2132231A in patients with unresectable and progressive metastatic cutaneous melanoma | Active not recruiting |
| 111476 | phase 2 | GSK2132231A Antigen-Specific Cancer Immunotherapeutic as first-line treatment of patients with unresectable metastatic melanoma | Active not recruiting |
| 111482 | phase 3 | GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resected melanoma | Active not recruiting |
| 111714 | phase 1 | Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in association with chemotherapy in patients with unresectable and progressive metastatic cutaneous melanoma | Active not recruiting |